Buy Piqray (alpelisib) Online

$5,785.00

Disease Indications: Breast Cancer

Manufacturer: Novartis

Usage: Oral

Medicine approved by:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Piqray (alpelisib) is prescribed alongside fulvestrant to treat advanced or metastatic breast cancer in postmenopausal women and men. This combination therapy targets hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with PIK3CA mutation, identified by an FDA-approved test, after progression on prior endocrine-based treatment.